眼镜蛇毒因子抑制补体激活对脓毒症大鼠血清细胞因子的影响(4)
[14]翟红霞，姚咏明，陆连荣，等.烫伤大鼠组织肿瘤坏死因子mRNA表达与内毒素血症的关系[J].中华整形烧伤外科杂志，1999，15(6)：424-427.
[15]隰建成，马远征，周宝桐，等.创伤性脓毒症外周血中性粒细胞及组织中肿瘤坏死因子-αmRNA表达的变化[J].中国危重病急救医学，2006，18(1)：28-31.
[16] Eks L，Gillrie M R，Li L，et al.Leukotriene B4-Mediated Neutrophil Recruitment Causes Pulmonary Capillaritis during Lethal Fungal Sepsis[J].Cell Host Microbe，2018，23(1)：121-133.
[17] Denk S，Taylor R P，Wiegner R，et al.Complement C5a-induced changes in neutrophil morphology during inflammation[J].Scand J Immunol，2017，86(3)：143-155.
[18] Bosmann M，Ward P A.The inflammatory response in sepsis[J].Trends Immunol，2013，34(3)：129-136.
[19] Hattori Y，Hattori K，Suzuki T，et al.Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction：Novel therapeutic implications and challenges[J].Pharmacol Ther，2017，177(2)：56-66.
[20] Rosenthal M D，Moore F A.Persistent Inflammation，Immunosuppression，and Catabolism：Evolution of Multiple OrganDysfunction[J].Surg Infect(Larchmt)，2016，17(2)：167-172.
[21] van der Poll T.Immunotherapy of sepsis[J].Lancet Infect Dis，2001，1(3)：165-174.
[22] Hotchkiss R S，Monneret G，Payen D.Immunosuppression in sepsis：a novel understanding of the disorder and a new therapeutic approach[J].Lancet Infect Dis，2013，13(3)：260-268.
[23] Boomer J S，Green J M，Hotchkiss R S.The changing immune system in sepsis：is individualized immuno-modulatory therapy the answer？[J].Virulence，2014，5(1)：45-56.
[24] Patil N K，Bohannon J K，Sherwood E R.Immunotherapy：a promising approach to reverse sepsis-induced immunosuppression[J].Pharmacol Res，2016，111(2)：688-702.
(收稿日期：2018-02-07) (本文編辑：董悦), 百拇医药(魏乔 盛雅倩 茹松伟)
[15]隰建成，马远征，周宝桐，等.创伤性脓毒症外周血中性粒细胞及组织中肿瘤坏死因子-αmRNA表达的变化[J].中国危重病急救医学，2006，18(1)：28-31.
[16] Eks L，Gillrie M R，Li L，et al.Leukotriene B4-Mediated Neutrophil Recruitment Causes Pulmonary Capillaritis during Lethal Fungal Sepsis[J].Cell Host Microbe，2018，23(1)：121-133.
[17] Denk S，Taylor R P，Wiegner R，et al.Complement C5a-induced changes in neutrophil morphology during inflammation[J].Scand J Immunol，2017，86(3)：143-155.
[18] Bosmann M，Ward P A.The inflammatory response in sepsis[J].Trends Immunol，2013，34(3)：129-136.
[19] Hattori Y，Hattori K，Suzuki T，et al.Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction：Novel therapeutic implications and challenges[J].Pharmacol Ther，2017，177(2)：56-66.
[20] Rosenthal M D，Moore F A.Persistent Inflammation，Immunosuppression，and Catabolism：Evolution of Multiple OrganDysfunction[J].Surg Infect(Larchmt)，2016，17(2)：167-172.
[21] van der Poll T.Immunotherapy of sepsis[J].Lancet Infect Dis，2001，1(3)：165-174.
[22] Hotchkiss R S，Monneret G，Payen D.Immunosuppression in sepsis：a novel understanding of the disorder and a new therapeutic approach[J].Lancet Infect Dis，2013，13(3)：260-268.
[23] Boomer J S，Green J M，Hotchkiss R S.The changing immune system in sepsis：is individualized immuno-modulatory therapy the answer？[J].Virulence，2014，5(1)：45-56.
[24] Patil N K，Bohannon J K，Sherwood E R.Immunotherapy：a promising approach to reverse sepsis-induced immunosuppression[J].Pharmacol Res，2016，111(2)：688-702.
(收稿日期：2018-02-07) (本文編辑：董悦), 百拇医药(魏乔 盛雅倩 茹松伟)